Alec W Gibson1, Alipi V Bonm2, Jason Barber3, Jerome J Graber2,3. 1. School of Medicine, University of Washington, Seattle, Washington, USA. 2. Department of Neurology, University of Washington, Seattle, Washington, USA. 3. Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: Primary CNS lymphoma is a rare and aggressive cancer that can develop in immunocompetent individuals, but little is known about risk factors and causes of disease. Previous studies have demonstrated seasonal patterns for lymphomas and brain tumors. This study examined the seasonal incidence pattern for primary CNSlymphoma. METHODS: A retrospective review was performed for patients diagnosed with primary CNS lymphoma from 2000 through 2018 at our tertiary referral center. A total of 156 patients were categorized based on month of symptom onset, month of diagnosis, and month of recurrence if they experienced a relapse of their disease. The distributions were then analyzed for seasonal patterns. RESULTS: There was a significant, bimodal seasonal incidence pattern based on month of symptom onset (P < .001), with peaks in July (n = 19) and December (n = 23) and troughs in March (n = 4) and September (n = 5). There were no significant differences in patients' sex, age at presentation, length of follow-up, and progression-free survival across months. There were no seasonal patterns based on month of diagnosis (P = .450) or month of disease recurrence (P = .572). CONCLUSION: The incidence of primary CNS lymphoma has bimodal peaks in midsummer and early winter, which could provide insight into causative agents and mechanisms of disease.
BACKGROUND: Primary CNS lymphoma is a rare and aggressive cancer that can develop in immunocompetent individuals, but little is known about risk factors and causes of disease. Previous studies have demonstrated seasonal patterns for lymphomas and brain tumors. This study examined the seasonal incidence pattern for primary CNSlymphoma. METHODS: A retrospective review was performed for patients diagnosed with primary CNS lymphoma from 2000 through 2018 at our tertiary referral center. A total of 156 patients were categorized based on month of symptom onset, month of diagnosis, and month of recurrence if they experienced a relapse of their disease. The distributions were then analyzed for seasonal patterns. RESULTS: There was a significant, bimodal seasonal incidence pattern based on month of symptom onset (P < .001), with peaks in July (n = 19) and December (n = 23) and troughs in March (n = 4) and September (n = 5). There were no significant differences in patients' sex, age at presentation, length of follow-up, and progression-free survival across months. There were no seasonal patterns based on month of diagnosis (P = .450) or month of disease recurrence (P = .572). CONCLUSION: The incidence of primary CNS lymphoma has bimodal peaks in midsummer and early winter, which could provide insight into causative agents and mechanisms of disease.
Authors: Khê Hoang-Xuan; Eric Bessell; Jacoline Bromberg; Andreas F Hottinger; Matthias Preusser; Roberta Rudà; Uwe Schlegel; Tali Siegal; Carole Soussain; Ufuk Abacioglu; Nathalie Cassoux; Martina Deckert; Clemens M F Dirven; Andrés J M Ferreri; Francesc Graus; Roger Henriksson; Ulrich Herrlinger; Martin Taphoorn; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2015-07 Impact factor: 41.316
Authors: S Camilleri-Broët; A Martin; A Moreau; R Angonin; D Hénin; M F Gontier; M C Rousselet; S Caulet-Maugendre; P Cuillière; T Lefrancq; K Mokhtari; M Morcos; P Broët; M Kujas; J J Hauw; B Desablens; M Raphaël Journal: Am J Clin Pathol Date: 1998-11 Impact factor: 2.493
Authors: Sven Borchmann; Melita Cirillo; Helen Goergen; Lydia Meder; Stephanie Sasse; Stefanie Kreissl; Paul Jan Bröckelmann; Bastian von Tresckow; Michael Fuchs; Roland Tillmann Ullrich; Andreas Engert Journal: J Clin Oncol Date: 2019-10-17 Impact factor: 44.544
Authors: Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox Journal: Br J Haematol Date: 2022-03-16 Impact factor: 8.615